Adoptive cell therapy with NK cells in a murine CRC xenograft model with cetuximab demonstrated substantial tumor growth inhibition, primarily in EGFR-expressing tumor lines.111 NK-based cell therapy displays a favorable safety profile and does not depend on antigen recognition. This evidence concerns the gene EGFR and neoplasm.